PepGen Inc

Item 5. Other Information.

On February 8, 2024, Dr. James McArthur, our President and Chief Executive Officer, terminated a trading arrangement he had previously adopted with respect to the sale of our common stock that was intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c), referred to as a “Rule 10b5-1 Trading Plan”. Dr. McArthur’s Rule 10b5-1 Trading Plan wasadopted on December 8, 2022, had a term that ended on May 15, 2024 and provided for the sale of up to 125,000 shares of common stock pursuant to one or more limit orders. As of the date of termination of Dr. McArthur’s Rule 10b5-1 Trading Plan, Dr. McArthur had sold 31,250 shares of common stock under its terms.

On January 19, 2024, Dr. Michelle Mellion, our Senior Vice President, Clinical Development, adopted a Rule 10b5-1 Trading Plan which has a term that ends on June 16, 2025, and provides for the sale of up to 118,984 shares of common stock pursuant to one or more limit orders.

On January 23, 2024, Dr. Niels Svenstrup, our Senior Vice President, Chemistry, Manufacturing, and Controls, adopteda Rule 10b5-1 Trading Plan, which has a term that ends on December 15, 2025 and provides for the sale of up to 42,000 shares of common stock pursuant to one or more limit orders.